Suggested remit: To appraise the clinical and cost effectiveness of somapacitan within its marketing authorisation for treating children with growth hormone deficiency.
|
Status
|
In progress
|
|
Technology type
|
Medicine
|
|
Decision
|
Selected
|
|
Reason for decision
|
Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
|
| Process |
Cost Comparison Standard
|
| ID number |
6178
|
Project Team
Email enquiries
| External Assessment Group |
Newcastle NIHR TAR Team, Newcastle University |
Stakeholders
| Companies sponsors |
Novo Nordisk (somapacitan) |
| Others |
Department of Health and Social Care |
| |
NHS England |
| Patient carer groups |
Child Growth Foundation |
| Professional groups |
Royal College of Physicians |
| Associated public health groups |
None |
| Comparator companies |
Ipsen (somatropin) (confidentiality agreement not signed, not participating) |
| |
Lilly (somatropin) (confidentiality agreement not signed, not participating) |
| |
Merck Serono (somatropin) (confidentiality agreement not signed, not participating) |
| |
Novo Nordisk (somatropin) (confidentiality agreement not signed, not participating) |
| |
Pfizer (somatrogon, somatropin) (confidentiality agreement not signed, not participating) |
| |
Sandoz (somatropin) (confidentiality agreement not signed, not participating) |
| General commentators |
All Wales Therapeutics and Toxicology |
| |
Centre |
| |
British National Formulary |
| |
Department of Health, Social Services |
| |
and Public Safety for Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Medicines and Healthcare products |
| |
Regulatory Agency |
| |
Scottish Medicines Consortium |
| |
Welsh Government |
| |
Welsh Health Specialised Services |
| |
Committee |
| Relevant research groups |
None |
|
Date
|
Update
|
|
25 May 2023
|
Invitation to participate |
|
20 January 2023 - 17 February 2023
|
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6178 |
|
20 January 2023
|
In progress. Scoping commencing |
|
28 September 2022
|
Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual